• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

    2/13/24 6:17:56 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    SC 13G/A 1 d780097dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Generation Bio Co.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    37148K100

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 37148K100

     

     1.   

     Names of Reporting Persons

     

     BB Biotech AG

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Switzerland

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,608,280

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,608,280

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,608,280

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     5.5%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC, CO

    2 of 6


    CUSIP No. 37148K100

     

     1.   

     Names of Reporting Persons

     

     Biotech Growth N.V.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Curaçao

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,608,280

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,608,280

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,608,280

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     5.5%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

    3 of 6


    Item 1

    1(a) Name of Issuer: Generation Bio Co.

    1(b) Address of Issuer’s Principal Executive Offices:

    301 Binney Street, Cambridge, MA 02142, United States

    Item 2

    2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Growth N.V. (“Biotech Growth”)

    2(b) Address of Principal Business Office or, if none, Residence:

    BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

    Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

    2(c) Citizenship:    BB Biotech AG: Switzerland

    Biotech Growth N.V.: Curaçao

    2(d) Title of Class of Securities: Common Stock, $0.0001 par value

    2(e) CUSIP Number: 37148K100

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: 3,608,280

    (b) Percent of class: 5.5%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 0

    (ii) Shared power to vote or to direct the vote 3,608,280

    (iii) Sole power to dispose or to direct the disposition of 0

    (iv) Shared power to dispose or to direct the disposition of 3,608,280

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    This statement is filed jointly by BB Biotech and Biotech Growth, Biotech Growth is a wholly-owned subsidiary of BB Biotech.

     

    4 of 6


    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURES

    After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    BB Biotech AG

     

    Date: February 6, 2024     By:  

    /s/ Martin Gubler

          Signatory Authority
        Name:   Martin Gubler
        Title:   Signatory Authority
    Date: February 6, 2024     By:  

    /s/ Ivo Betschart

          Signatory Authority
        Name:   Ivo Betschart
        Title:   Signatory Authority
    Biotech Growth N.V.      
    Date: February 6, 2024     By:  

    /s/ Jan Bootsma

          Signatory Authority
        Name:   Jan Bootsma
        Title:   Signatory Authority
    Date: February 6, 2024     By:  

    /s/ Hugo van Neutegem

          Signatory Authority
        Name:   Hugo van Neutegem
        Title:   Signatory Authority

     

    5 of 6


    Exhibit Index

    Exhibit A: Agreement by and between BB Biotech AG and Biotech Growth N.V. with respect to the filing of this disclosure statement.*

     

     

    *

    Previously filed as an exhibit to BB Biotech AG and Biotech Growth N.V.’s Schedule 13G filed with the Securities and Exchange Commission on January 8, 2021.

     

    6 of 6

    Get the next $GBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    8/13/2025$7.00Outperform → Neutral
    Wedbush
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Paone Antoinette covered exercise/tax liability with 468 shares and converted options into 1,592 shares, increasing direct ownership by 3% to 35,465 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    7/17/25 4:10:10 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Howze Yalonda converted options into 3,347 shares and covered exercise/tax liability with 983 shares, increasing direct ownership by 13% to 21,101 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    7/17/25 4:10:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Conway Kevin John converted options into 587 shares and covered exercise/tax liability with 173 shares, increasing direct ownership by 2% to 18,273 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    7/17/25 4:10:12 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

    • New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell-driven autoimmune diseases • Company is evaluating strategic alternatives to maximize value of its delivery system and potential therapeutics for T cell-driven autoimmune diseases for shareholders • Cash balance of $141.4M as of June 30, 2025 • Recent litigation settlement extinguishes lease liability CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's p

    8/12/25 4:05:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Announces 1-for-10 Reverse Stock Split

    CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-shar

    7/18/25 8:35:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company's 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee's entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received non-statutory stock options stock options to purchase an aggregate of 128,600 shares of the company's common stock. The options have an exercise price of $0.32 per share, wh

    7/7/25 4:05:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Generation Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Generation Bio from Outperform to Neutral and set a new price target of $7.00

    8/13/25 8:02:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by TD Cowen

    TD Cowen downgraded Generation Bio from Outperform to Market Perform

    10/19/23 7:43:32 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Generation Bio with a new price target

    Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00

    11/8/22 6:17:49 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    1/14/25 4:05:17 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/11/23 4:30:19 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/6/23 4:30:13 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

    Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

    2/6/25 5:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

    Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea

    5/10/23 4:15:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

    CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th

    4/5/23 7:30:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    11/14/24 1:22:38 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    2/14/24 10:03:03 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.

    SCHEDULE 13G/A - Generation Bio Co. (0001733294) (Subject)

    8/14/25 1:07:20 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Generation Bio Co.

    10-Q - Generation Bio Co. (0001733294) (Filer)

    8/12/25 4:15:52 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Generation Bio Co. (0001733294) (Filer)

    8/12/25 4:10:08 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care